A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis [EXTENSION OF 700050940]
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Sponsors Roche
- 05 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 20 Jan 2014 Planned End Date changed from 1 Apr 2015 to 1 Jun 2015, according to Clinicaltrials.gov record.
- 09 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.